Index. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers

Transcription

1 Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) a-adrenergic blockers for PTSD, 798 b-adrenergic blockers for PTSD, 798 Adrenergic receptor gene in ADHD, Aggression psychotropic medications for, a 2 -Agonist(s) for ADHD, 949 Amphetamine(s) for ADHD, for narcolepsy, Amphetamine salts mixed for bipolar disorder, 920 AN. See Anorexia nervosa (AN) Anorexia nervosa (AN) diagnostic criteria for, 838 pharmacotherapy for, antidepressants, 839 antipsychotics, 839 bisphosphonates, 840 investigational agents, 840 tranquilizers, 840 Anticonvulsant(s) for BED, 844 for bipolar disorder, 913, 921 Anticonvulsant hypersensitivity syndrome mood stabilizers and, Antidepressant(s). See also specific drugs adverse effects of, for AN, 839 for bipolar depression, for BN, for cataplexy, 872 for depression acute phase, Child Adolesc Psychiatric Clin N Am 21 (2012) childpsych.theclinics.com /12/$ see front matter ª 2012 Elsevier Inc. All rights reserved.

2 976 Antidepressant(s) (continued ) discontinuation syndrome associated with, 819 long-term effects of, manic switching/activation syndrome associated with, 818 for narcolepsy, 872 safety of, serotonin syndrome associated with, 819 side effects of cardiotoxicity, management of, somatic, suicidality, , 818 tricyclic for depression, 817 Antihistamines for insomnia, 863 Antipsychotics. See also specific agents for AN, 839 for bipolar disorder, for EOS monitoring of, for psychotic disorders, manic disorders, and ASDs efficacy and adverse effects of polymorphisms effects on, 779 second-generation for bipolar disorder, long-term evidence of, side effects of management of, movement disorders, Anxiety psychotropic medications for, bipolar disorder with medications for, 927 described, drug metabolism in, 777 pharmacogenomics for, Anxiety disorders treatment of, 821 general principles of, 790 psychopharmacologic, See also specific disorders and drugs adverse effects of, clinical considerations related to, future directions in, Aripiprazole for AN, 834 for bipolar disorder, 914, 922 for EOS, Armodafinil for narcolepsy, 872

3 Atomoxetine for ADHD, for BED, 834 for bipolar disorder, 919 Attention-deficit/hyperactivity disorder (ADHD), , bipolar disorder with medications for, drug metabolism in, 776 medications for, 821, , a 2 -agonists, 949 amphetamine, atomoxetine, comorbidity associated with, 950 described, 941, 943 empiric evidence for, longitudinal course of treatment, 950 methylphenidate, non FDA-approved, stimulants, 919, melatonin for, pharmacogenomics for, clinical results of, 776 psychotropic medications effects in studies related to, behavior-related, combination therapy, 758 fmri in, 756 fnirs in, MRS in, 757 for prefrontal region, 757 structural MRI in, Augmentation treatment of, 822 Autism psychotropic medications effects in studies related to, 758 Autism spectrum disorders (ASDs), 758, bipolar disorder with medications for, described, 957 drug metabolism in, medications for antipsychotics efficacy and adverse effects of polymorphisms effects on, 779 measuring change due to, melatonin, 868 psychotropic, , See also Psychotropic medications, for ASDs pharmacogenomics for, problem behaviors associated with differential diagnosis of,

4 978 Autism (continued ) psychopathology in comorbid, psychopharmacology of, types of, 957 B Bariatric surgery for BED, 844 BED. See Binge-eating disorder (BED) Behavior(s) problem ASD associated differential diagnosis of, Benzodiazepines for GAD, 794 for insomnia, for parasomnias, for SAD, 794 for social phobia, 794 Binge-eating disorder (BED) diagnostic criteria for, 838 pharmacotherapy for, , Bipolar depression described, 924 medications for, antidepressants, lamotrigine, lithium, 924 quetiapine, 925 Bipolar disorder at-risk youth for interventions for, ethical issues in, 741 evidence-based, future directions in, in presence of comorbid conditions, comorbid conditions with medications for, ADHD, anxiety, 927 ASDs, substance use disorders, 927 depression with, See also Bipolar depression described, diagnostic criteria for, 912 future directions for, medications for, for acute manic and mixed episodes, , anticonvulsants, 913, 921

5 979 antipsychotics, combination therapy, dosing and effectiveness of, empiric evidence for, future directions for, lithium, long-term evidence of, mood stabilizers, long-term evidence of, psychotropic, See also Bipolar disorder, psychotropic medications effects in SGAs, long-term evidence of, vs. mood stabilizers, overview of, , psychotropic medications effects in studies related to, differential neural effects, 760 fmri in, lithium treatment, 761 medication outcomes, 762 MRS in, multimodal neuroimaging, 760 prefrontal neurometabolite concentrations, recurrence of, 912 Bisphosphonates for AN, 840 BN. See Bulimia nervosa (BN) Breathing sleep-disordered, 873 Brief psychosocial intervention in depression assessment, Bulimia nervosa (BN) diagnostic criteria for, 838 pharmacotherapy for, antidepressants, investigational agents, light therapy, naloxone, 842 naltrexone, 842 topiramate, 842 Bupropion for depression, 816 for obesity, 834, 846 Buspirone for GAD, SAD, and social phobia, 794 C Carbamazepine for bipolar disorder, , 921

6 980 Cataplexy medications for antidepressants, 872 CATIE. See Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Childhood-onset schizophrenia (COS) medications for, See also Early-onset schizophrenia (EOS) Chloral hydrate for insomnia, Citalopram for BED, 834 for depression, 812 Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), Clomipramine for OCD, 796 Clonazepam for parasomnias, 876 Clonidine for insomnia, Clozapine for EOS, Communication social deficits in psychotropic medications for, COS. See Childhood-onset schizophrenia (COS) Cyproheptadine for AN, 834 D Depression, assessment of, brief psychosocial intervention, initial, 808 ongoing, bipolar medications for, See also Bipolar depression complex cases of treatment of, brief adjunctive medication in, comorbid conditions related, described, 808 medications for, acute treatment, SSRIs in, antidepressants adverse effects of, safety of, continuation treatment, maintenance treatment,

7 981 refractory depression, MAOIs, 817 non-ssris, SSRIs, 814 TCAs, 817 refractory medications for, 814 Depressive disorders, See also Depression drug metabolism in, 777 pharmacogenomics for, psychotropic medications effects in studies related to, 762 types of, 808 Diethylpropion for obesity, 834, 846 Diphenhydramine for insomnia, 863, 864, 866 Discontinuation syndrome antidepressants and, 819 Divalproex for bipolar disorder, 913 Dopamine receptor gene in ADHD, 775 Dopamine transporter gene in ADHD, 775 Duloxetine for BED, 835 for depression, 816 DVPX for bipolar disorder, 917 E Early-onset psychosis. See also Early-onset schizophrenia (EOS) medications for empirical evidence for, overview of, Early-onset schizophrenia (EOS) long-term course of, 893 medications for, aripiprazole, clinical trials of, clozapine, empirical evidence for, FGAs, 889 future directions in, 902 monitoring of, olanzapine, 890 paliperidone, 892 quetiapine, 891 risperidone,

8 982 Early-onset (continued) SGAs, TEOSS study, ziprasidone, 891 overview of, workup of, Eating disorders. See also Anorexia nervosa (AN); Binge-eating disorder (BED); Bulimia nervosa (BN); Obesity comorbid conditions associated with, diagnosis and treatment of, 847 complications of psychopharmacologic treatment of, 847 medication-related, mortality associated with, 832 pharmacokinetics of, psychopharmacologic treatment of, surgical management of pharmacokinetics related to, EOS. See Early-onset schizophrenia (EOS) Epilepsy parasomnias vs., 875 Escitalopram for BED, 835 Eszopiclone for insomnia, Ethical issues in interventions for youth at high risk for bipolar disorder and schizophrenia, 741 Exenatide for obesity, 835 F Fear described, FGAs. See First-generation agents (FGAs) First-generation agents (FGAs) for EOS, 889 Fluoxetine for BED, 835 for BN, 835 for depression, Fluvoxamine for depression, 813 fmri. See Functional MRI (fmri) fnirs. See Functional near-infrared spectroscopy (fnirs) Functional MRI (fmri) in ADHD, 756 in bipolar disorder, Functional near-infrared spectroscopy (fnirs) in ADHD,

9 983 G Gabapentin for RLS, 874 GAD. See Generalized anxiety disorder (GAD) Generalized anxiety disorder (GAD) medications for, H Hyperactivity-impulsivity psychotropic medications for, Hyperarousal psychotropic medications for, Hypertensive agents for insomnia, Hypnotics for insomnia, off-label use, 870 I Inattention psychotropic medications for, Insomnia, medications for, antihistamines, 863 benzodiazepines, chloral hydrate, clonidine, diphenhydramine, 863, 864, 866 hypertensives, hypnotics, off-label use, 870 melatonin, neuroleptics off-label use, 870 ramelteon, 868 stimulants and, Irritability psychotropic medications for, K Kidney(s) mood stabilizers effects on, 727

10 984 L Lamotrigine for bipolar depression, for bipolar disorder, 913, 917 Levodopa for RLS, Liraglutide for obesity, 835 Lithium for bipolar depression, 924 for bipolar disorder, , 918 neural effects of studies related to, 761 Lorcaserin for obesity, 835 M Magnetic resonance imaging (MRI) structural in ADHD, Magnetic resonance spectroscopy (MRS) in ADHD, 757 in bipolar disorder, Major depressive disorder (MDD) with psychotic features treatment of, 821 Manic disorders antipsychotics for efficacy and adverse effects of polymorphisms effects on, 779 drug metabolism in, pharmacogenomics for, Manic switching/activation syndrome antidepressants and, 818 MAOIs. See Monoamine oxide inhibitors (MAOIs) Melatonin for insomnia, Metabolic syndrome antipsychotics and side effects of, Metformin for obesity, 835, 845 Methylphenidate for ADHD, for bipolar disorder, 919 Mirtazapine for depression, 816 Mixed amphetamine salts for bipolar disorder, 920

11 985 Modafinil for narcolepsy, 872 Monoamine oxide inhibitors (MAOIs) for depression, 817 Mood stabilizers for bipolar disorder, long-term evidence of, vs. SGAs, side effects of anticonvulsant hypersensitivity syndrome, management of, renal toxicity, 727 suicidality, 724 Movement disorders antipsychotics and side effects of, MRS. See Magnetic resonance spectroscopy (MRS) MTA. See Multimodal Treatment Study of Children with ADHD (MTA) Multimodal Treatment Study of Children with ADHD (MTA), N Naloxone for BN, 842 Naltrexone for BN, 836, 842 Narcolepsy, described, medications for amphetamines, antidepressants, 872 sodium oxybate, 871 Neurodevelopmental disorders melatonin for, 868 Neuroimaging multimodal in bipolar disorder, 760 Neuroleptics for insomnia off-label use, 870 Nocturnal seizures parasomnias vs., 875 O Obesity. See also Eating disorders comorbid conditions associated with, mortality associated with, 832 prevalence of, psychopharmacologic treatment of, in adults, 846

12 986 Obesity (continued) described, diethylpropion, 846 medications in development, 846, metformin, 845 orlistat, 845 phendimetrazine, 846 phentermine, 846 topiramate, 845 surgical management of pharmacokinetics related to, Obsessive-compulsive disorder (OCD) psychotropic medications for, medications for, psychotropic effects of, Obstructive sleep apnea (OSA), 873 OCD. See Obsessive-compulsive disorder (OCD) Olanzapine for AN, 836 for bipolar disorder, 914, 921 for EOS, 890 Ondansetron for BN, 836 Orlistat for obesity, 836, 845 OSA. See Obstructive sleep apnea (OSA) Oxcarbazepine for bipolar disorder, 918, 921 P Paliperidone for EOS, 892 Panic disorder medications for, Parasomnias, described, epilepsy vs., 875 medications for, nocturnal seizures vs., 875 Parental expectations as factor in sleep disorders in youth, 862 Paroxetine for depression, PATS. See Preschool ADHD Treatment Study (PATS) Phendimetrazine for obesity, 836, 846 Phentermine for obesity, 836, 846

13 Phentermine-topiramate for obesity, 836 Phobia(s) social medications for, Physical growth stimulants and, Posttraumatic stress disorder (PTSD) pharmacologic management of, Pramipexole for RLS, 874 Pramlintide for obesity, 837 Prefrontal neurometabolite concentrations in bipolar disorder studies related to, Preschool ADHD Treatment Study (PATS), Psychiatric pharmacogenomics overview of, in pediatric psychopharmacology, See also specific disorders ADHD, anxiety, ASDs, cost and availability of, 780 depression, future directions in, indications for, manic disorders, psychotic disorders, Psychopathology prevalence of, 753 Psychopharmacologic agents for anxiety disorders, See also specific disorders and drugs and Anxiety disorders, treatment of, psychopharmacologic Psychopharmacology pediatric psychiatric pharmacogenomics in, Psychosis(es) early-onset, See also Childhood-onset schizophrenia (COS); Early-onset psychosis; Early-onset schizophrenia (EOS) Psychotic disorders. See also specific types antipsychotics for efficacy and adverse effects of polymorphisms effects on, 779 drug metabolism in, pharmacogenomics for, Psychotropic medications. See also specific drugs appropriate and judicious use of, patient assessment in, multiple informants, 706 nonspecific symptoms,

14 988 Psychotropic (continued) ordering medical work-up and consulting colleagues, 706 presentation-related, rating scales, 705 understanding development, 704 treatment plan development in, adverse effects discussion, biosocial formulation, 707 evidence-based medication selection, 709 facilitating earlier psychiatric consultation, feasibility issues, limiting total number of medications, maintaining gains made, 710 monitoring efficacy and adverse effects, 710 pre-existing medication regimen review, 709 pretreatment baseline, 708 psychosocial interventions, 707 target identification, titrating doses, 710 treatment goal identification, 708 for ASDs, , evidence base for, aggression, anxiety, hyperactivity-impulsivity, hyperarousal, inattention, irritability, OCD, repetitive behavior/stereotypy, self-injury, 968 self-regulation deficits, sleep disturbance, 968 social communication deficits, neural effects of, See also specific disorders, e.g., Attention deficit with hyperactivity disorder (ADHD) overview of, studies related to, See also specific disorders, e.g., Bipolar disorder autism, 758 bipolar disorder, depressive disorders, 762 methods, 754 OCD, results, schizophrenia, side effects of management of, antidepressants, antipsychotics, described, 714 mood stabilizers,

15 989 stimulants, neural, See also Psychotropic medications, neural effects of PTSD. See also Posttraumatic stress disorder (PTSD) Q Quetiapine for AN, 837 for bipolar depression, 925 for bipolar disorder, 915, for EOS, 891 R Ramelteon for insomnia, 868 Repetitive behavior/stereotypy psychotropic medications for, Restless legs syndrome (RLS), Risperidone, for bipolar disorder, 915, 921 for PTSD, 798 RLS. See Restless legs syndrome (RLS) Ropinirole for RLS, 874 Rotigotine for RLS, 874 S SAD. See Separation anxiety disorder (SAD) Schizophrenia at-risk youth for interventions for, ethical issues in, 741 evidence-based, future directions in, in presence of comorbid conditions, childhood-onset, early-onset, See also Early-onset schizophrenia (EOS) overview of, psychotropic medications effects in studies related to, Second-generation antipsychotics (SGAs) for bipolar disorder, long-term evidence of, vs. mood stabilizers, for EOS, Seizure(s) nocturnal parasomnias vs., 875

16 990 Selective serotonin reuptake inhibitors (SSRIs) adverse effects of, for BED, 843 for depression, acute phase, refractory, 814 for GAD, for OCD, for PTSD, for SAD, for social phobia, Self-injury psychotropic medications for, 968 Self-regulation deficits in psychotropic medications for, Separation anxiety disorder (SAD) medications for, Serotonin-norepinephrine reuptake inhibitors (SNRIs) for GAD, SAD, and social phobia, Serotonin syndrome antidepressants and, 819 Sertraline for BED, 837 for BN, 837 for depression, 812 SGAs. See Second-generation antipsychotics (SGAs) Sibutramine for BED, 843 Sleep apnea obstructive, 873 Sleep development in youth, Sleep-disordered breathing, 873 Sleep disorders, See also specific types and Sleep medications psychotropic medications for, 968 insomnia, narcolepsy, off-label medications for, 862 OSA, 873 overview of, 861 parasomnias, parental expectations and, 862 RLS, sleep-disordered breathing, 873 Sleep medications dosage, 863 general principles of,

17 991 off-label, 862 reactions to, special considerations, 862 Sleep pharmacology, See also Sleep disorders; Sleep medications Social communication deficits in psychotropic medications for, Social phobia medications for, Sodium oxybate for insomnia, 871 SSRIs. See Selective serotonin reuptake inhibitors (SSRIs) Stimulants for ADHD, 919, MTA on, PATS on, side effects of cardiotoxicity, 729 insomnia, management of, physical growth, Structural MRI in ADHD, Substance use disorders bipolar disorder with medications for, 927 treatment of, 821 Suicidality antidepressants and, , 818 mood stabilizers and, 724 T TCAs. See Tricyclic antidepressants (TCAs) TEOSS study. See Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS) study Topiramate for BED, 837 for bipolar disorder, 919, 921 for BN, 837, 842 for obesity, 845 Tranquilizers for AN, 840 Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS) study, Tricyclic antidepressants (TCAs) for depression, 817 V Venlafaxine for atypical AN, 837 for depression,

18 992 W Weight medication-related changes in, Z Zaleplon for insomnia, Ziprasidone for bipolar disorder, 916, 922 for EOS, 891 Zolpidem for insomnia,